Corbin Therapeutics Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $748K
Latest Deal Amount
  • Investors
  • 1

Corbin Therapeutics General Information


Provider of a drug discovery platform. The company's biotechnology platform develops drugs from ubiquitin carboxyl-terminal hydrolase 15 (USP15) enzyme to treat various inflammation-based diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Social/Platform Software
Drug Discovery
Primary Office
  • 227 Westminster North
  • Montreal, Quebec H4X 1Z5
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Corbin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 09-Jan-2017 $748K 00000 Completed Startup
To view Corbin Therapeutics’s complete valuation and funding history, request access »

Corbin Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Maxime Ranger Ph.D Chief Executive Officer & President
To view Corbin Therapeutics’s complete executive team members history, request access »

Corbin Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
GeneChem Venture Capital Minority 000 0000 000000 0
To view Corbin Therapeutics’s complete investors history, request access »